Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Adolescents With Chronic Hepatitis C Virus: Part 1 of the DORA Study-Reference-Cited by-同舟云学术

Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Adolescents With Chronic Hepatitis C Virus: Part 1 of the DORA Study

Published:2019-08-13 Issue:2 Volume:71 Page:456-462
ISSN:0270-9139
Container-title:Hepatology
language:en
Short-container-title:Hepatology

Author:

Jonas Maureen M.¹²,Squires Robert H.³⁴,Rhee Susan M.⁵,Lin Chih‐Wei⁶,Bessho Kazuhiko⁷,Feiterna‐Sperling Cornelia⁸,Hierro Loreto⁹,Kelly Deirdre¹⁰,Ling Simon C.¹¹,Strokova Tatiana¹²,Valle‐Segarra Antonio¹³,Lovell Sandra⁵,Liu Wei⁵,Ng Teresa I.⁵,Porcalla Ariel⁵,Gonzalez Yuri Sanchez⁵,Burroughs Margaret⁵,Sokal Etienne¹⁴^ORCID

Affiliation:

1. Division of Gastroenterology, Hepatology, and Nutrition Boston Children's Hospital Boston MA

2. Department of Pediatrics Harvard Medical School Boston MA

3. Division of Gastroenterology, Hepatology, and Nutrition UPMC Children's Hospital of Pittsburgh Pittsburgh PA

4. Department of Pediatrics University of Pittsburgh School of Medicine Pittsburgh PA

5. AbbVie Inc. North Chicago IL

6. Amgen Inc. Thousand Oaks CA

7. Osaka University Hospital Osaka Japan

8. Charité ‐ Universitaetsmedizin Berlin Berlin Germany

9. Hospital Universitario La Paz Madrid Spain

10. Birmingham Women's & Children's Hospital Birmingham United Kingdom

11. Division of Gastroenterology, Hepatology & Nutrition, The Hospital for Sick Children, and Department of Paediatrics University of Toronto Toronto Ontario Canada

12. Federal Research Centre of Nutrition and Biotechnology Moscow Russian Federation

13. San Jorge Children's Hospital San Juan Puerto Rico

14. Cliniques Universitaires Saint‐Luc Université Catholique de Louvain Brussels Belgium

Funder

AbbVie

Publisher

Wiley

Subject

Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hep.30840

Reference18 articles.